MedPath

Compression Device Safety Study on Edema

Phase 2
Completed
Conditions
Edema
Interventions
Device: Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs
Device: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs
Registration Number
NCT00732719
Lead Sponsor
ConvaTec Inc.
Brief Summary

To evaluate the safety of the prototype Compression Device in subjects with Oedema

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Subjects aged between 18 and 80, willing and able to provide written informed consent, and able to wear the device and follow the requirements of the protocol
  • Subjects who have an ankle to brachial pressure index (ABPI) of at least 0.8.
  • Subjects who suffer from chronic oedema (i.e. CEAP classification of C3, C4 or C5 1.)
  • Subjects who have Chronic Venous Insufficiency (CVI), which has been present for 6 weeks or longer and who have refluxes >0.5 sec in one or more major venous segments, superficial or deep or both (CEAP classification: C3-C5 1.; Ep,s; As,d; Pr).
Read More
Exclusion Criteria
  • Subjects with a history of skin sensitivity to any of the components of the study product.
  • Subjects who have previously been entered into the study before
  • Subjects who have a history of Deep Vein Thrombosis (DVT) within the last 6 months
  • Subjects who have an active leg ulcer (i.e. CEAP classification of C6 1).
  • Subjects with active cardiac disease or significant history of cardiac disease (including history of myocardial infarction, heart failure, valvular disease, arrhythmia and those with a pacemaker or have previously had a pacemaker).
  • Subjects who have initiated treatment or changed the dose within the past month of pharmaceutical agents that reduce clotting e.g. aspirin (except low-dose aspirin), anti-platelets, anti-coagulants and coumarin.
  • Subjects who are currently taking pharmaceutical agents that can modify the amount of leg oedema (e.g., diuretics, dihydropyridine calcium channel blockers, phlebotonic drugs, or fluctuating doses of systemic steroids) or have taken these agents within the last 10 days.
  • Subjects who are pregnant
  • Subjects who have worn compression therapy in the last 48 hours
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Profile APrototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffsDevice worn; no pressure given (placebo)
Profile BPrototype device(unnamed)-A battery operated inflatable pneumatic cuffsFoot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 30 mm Hg and upper cuff at 20mm Hg
Profile CPrototype device(unnamed)-A battery operated inflatable pneumatic cuffsFoot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 20 mm Hg and upper cuff at 10mm Hg
Profile EPrototype device(unnamed)-A battery operated inflatable pneumatic cuffsFoot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 40 mm Hg and upper cuff at 40mm Hg
Profile FPrototype device(unnamed)-A battery operated inflatable pneumatic cuffsFoot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 30 mm Hg and upper cuff at 30mm Hg
Profile GPrototype device(unnamed)-A battery operated inflatable pneumatic cuffsFoot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 20 mm Hg and upper cuff at 20mm Hg
Profile DPrototype device(unnamed)-A battery operated inflatable pneumatic cuffsFoot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 10 mm Hg and upper cuff at 0mm Hg
Primary Outcome Measures
NameTimeMethod
Volume reduction
Oedema reduction
The nature and incidence of adverse events
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hautarzt Phlebologe Allergologe

🇩🇪

Freiburg, Germany

© Copyright 2025. All Rights Reserved by MedPath